Avoid common mistakes on your manuscript.
Chronic lymphocytic leukemia (CLL) is the most common leukemia in the western world and is considered to be incurable. In the last 10 years, novel therapeutics, like B cell receptor blockers and the bcl‑2 inhibitor venetoclax have transformed the prognosis for CLL patients [1]. In this issue of the Magazine of European Medical Oncology (MEMO), we discuss the perspectives of novel strategies to actually cure CLL patients.
Daniel Heintel reviews the current treatment options for patients with CLL with respect to potential optimal treatment combinations [2]. Katharina Prochazka analyzes the effects and consequences of venetoclax-based regimens to induce deep remissions [3] and Jan-Paul Bohn presents the perspectives of a potentially bright future with new targets and drugs for CLL.
References
Cited Literature
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131:2745–60.
Heintel D. BTKi, venetoclax, obinutuzumab: what is the ideal combination?. memo. 2021. https://doi.org/10.1007/s12254-021-00776-4.
Prochazka KT, Uhl B. Bcl2 inhibitor venetoclax +/− Anti-CD20: what do deep remissions mean?. memo. 2021. https://doi.org/10.1007/s12254-021-00778-2.
Further Reading
Bohn J-P. New actionable targets and investigational drugs in chronic lymphocytic leukemia. memo. 2021. https://doi.org/10.1007/s12254-021-00755-9.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
P. Staber has received honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Takeda, Bristol-Myers Squibb, Novartis, BeiGene, Incyte, GlaxoSmithKline, Janssen, Roche, MedMedia, Astra Zeneca, AbbVie, Amgen, Medahead, Sanofi, Merck Sharp & Dome.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Staber, P. New frontiers in chronic lymphocytic leukemia on the way to curing the disease. memo 15, 3 (2022). https://doi.org/10.1007/s12254-022-00795-9
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12254-022-00795-9